Investors

ANNOUNCEMENT

bonyf successfully lists on Euronext Access Paris

on 17 March 2022

  • 01 March 2022

    European Medicines Agency (EMA) accepts marketing
    authorisation application for daprodustat.

  • 28 February 2022

    GSK introduces Haleon to investors

  • 28 February 2022

    GSK provides further update on phase III RSV maternal
    vaccine candidate programme

  • 01 March 2022

    European Medicines Agency (EMA) accepts marketing
    authorisation application for daprodustat.

Documentation & Press Releases

General Information

Why does bonyf go public?

  • To increase visibility, credibility and awareness. bonyf will be the first oral/dental care company listed on Euronext Paris;
  • Enter into licensing agreements with larger companies;
  • Invest in new product development and further clinical studies;
  • Create brand and product awareness.

How do I subscribe to buy bonyf shares?

You must have an account with a bank, stockbroker, online broker etc. Choose between either a securities account or a stock savings plan. When you subscribe to bonyf shares internationally, your bank will need the Mnemonic Code MLBON and the ISIN (International Securities Identification Number) Code BE6333353298. See technical information below.

Technical Information

Registration procedure: Technical admission
Number of shares admitted: 588,600
Share price: € 12
Company value at registration: € 7,063,200
ISIN Code: BE6333353298
Mnemonic Code: MLBON

The operation is being carried out in the context of a listing procedure on the Euronext Access market, by way of technical admission of bonyf shares. It does not require the approval of the French Financial Market Authorities (Autorité des Marchés Financiers) in accordance with the guidelines of the Euronext Access market.

Shareholder Information

ISIN Code:
BE6333353298
Ticker:
MLBON
Market:
Euronext Access Paris
ICB classification:
20103015 – Pharmaceutical

Breakdown of Share Capital Pre-listing on Euronext Access

ShareholdersNo. of Shares% of Share CapitalVoting Rights% of Voting Rights
Jean-Pierre Bogaert 295,47450.20%295,47450.20%
Ginette Buyle293,12549.80%293,12549.80%
Other1< 0.01%1< 0.01%

In the press

01 March 2022
European Medicines Agency (EMA) accepts marketing
authorisation application for daprodustat.

28 February 2022
GSK introduces Haleon to investors

28 February 2022
GSK provides further update on phase III RSV maternal
vaccine candidate programme

For any questions about Investor Relations

please contact our team

Jean-Pierre Bogaert
Founder and CEO

Dr Bart de Wever
Chief Scientific Officer

Timothy Foubert
Chief Financial Officer

CapValue
Investor & Press Relations